Zacchetti A - Search Results

1

(177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts.

Zacchetti A, Coliva A, Luison E, Seregni E, Bombardieri E, Giussani A, Figini M, Canevari S. Zacchetti A, et al. Nucl Med Biol. 2009 Oct;36(7):759-70. doi: 10.1016/j.nucmedbio.2009.05.004. Epub 2009 Jul 29. Nucl Med Biol. 2009. PMID: 19720288

2

90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.

Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, Canevari S. Coliva A, et al. Among authors: zacchetti a. Cancer Immunol Immunother. 2005 Dec;54(12):1200-13. doi: 10.1007/s00262-005-0693-2. Epub 2005 May 31. Cancer Immunol Immunother. 2005. PMID: 15926078 Free PMC article.

3

Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer.

Zacchetti A, Martin F, Luison E, Coliva A, Bombardieri E, Allegretti M, Figini M, Canevari S. Zacchetti A, et al. J Nucl Med. 2011 Dec;52(12):1938-46. doi: 10.2967/jnumed.110.086819. Epub 2011 Nov 8. J Nucl Med. 2011. PMID: 22068897 Free article.

4

Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.

Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, Mortarino M, Di Cioccio V, Maurizi G, Allegretti M, Canevari S. Figini M, et al. Among authors: zacchetti a. Cancer Immunol Immunother. 2009 Apr;58(4):531-46. doi: 10.1007/s00262-008-0575-5. Epub 2008 Aug 15. Cancer Immunol Immunother. 2009. PMID: 18704410 Free PMC article.

5

Tumor initiating cells: development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension.

Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A, Alison MR, Miotti S. Bortolomai I, et al. Among authors: zacchetti a. Cell Cycle. 2010 Mar 15;9(6):1194-206. doi: 10.4161/cc.9.6.11108. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20237414 Free article.

6

Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines.

Adobati E, Zacchetti A, Perico ME, Cremonesi F, Rasi G, Vallebona PS, Hagenaars M, Kuppen PJ, Pastan I, Panza L, Russo G, Colnaghi MI, Canevari S. Adobati E, et al. Among authors: zacchetti a. Histochem J. 1999 Nov;31(11):729-37. doi: 10.1023/a:1003900631953. Histochem J. 1999. PMID: 10646838

7

Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of KI-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry.

Zacchetti A, van Garderen E, Teske E, Nederbragt H, Dierendonck JH, Rutteman GR. Zacchetti A, et al. APMIS. 2003 Mar;111(3):430-8. doi: 10.1034/j.1600-0463.2003.t01-1-1110208.x. APMIS. 2003. PMID: 12752223

8

Immunohistochemical evaluation of p53 expression with different antibodies in malignant canine tumours with or without p53 gene mutation.

Zacchetti A, van Garderen E, Rutteman GR. Zacchetti A, et al. Vet Comp Oncol. 2007 Jun;5(2):108-18. doi: 10.1111/j.1476-5829.2006.00120.x. Vet Comp Oncol. 2007. PMID: 19754794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters